Literature DB >> 20049446

Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis.

Kumi Shidara1, Eisuke Inoue, Eiichi Tanaka, Daisuke Hoshi, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi, Hisashi Yamanaka.   

Abstract

The anti-cyclic citrullinated peptide (CCP) antibody has become increasingly important in the diagnosis of rheumatoid arthritis (RA), especially for early diagnosis. The purpose of this study is to compare the diagnostic usefulness of the second and third generation anti-CCP antibody kits among Japanese patients with RA. Anti-CCP antibody titers were measured with the second generation (MESACUP CCP test, Medical and biological laboratories) and third generation (QUANTA Lite CCP3 IgG ELISA, Inova Diagnostics) kits using serum samples from 106 rheumatoid arthritis (RA) patients and 57 non-RA patients. Sensitivities and specificities were compared. The sensitivity and specificity of the second generation anti-CCP (anti-CCP2) kit were 88.7 and 89.5%, and those of the third generation anti-CCP (anti-CCP3) kit were 91.5 and 87.7%. Area under the receiver operating curve showed that anti-CCP2 and anti-CCP3 had similar diagnostic performances. Diagnostic performance of the anti-CCP3 assay was comparable with the anti-CCP2 assay in Japanese patients with RA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049446     DOI: 10.1007/s00296-009-1336-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

1.  Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study.

Authors:  Benazir Saleem; Andrew K Brown; Helen Keen; Sharmin Nizam; Jane Freeston; Zunaid Karim; Mark Quinn; Richard Wakefield; Elizabeth Hensor; Philip G Conaghan; Paul Emery
Journal:  Arthritis Rheum       Date:  2009-07

Review 2.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Jowett; S Bryan; W Clark; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2006-11       Impact factor: 4.014

3.  Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis.

Authors:  N Bizzaro; G Mazzanti; E Tonutti; D Villalta; R Tozzoli
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

4.  A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis.

Authors:  F A van Gaalen; H Visser; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

5.  Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.

Authors:  Toshihiro Matsui; Kota Shimada; Naoko Ozawa; Hiromi Hayakawa; Futoshi Hagiwara; Hisanori Nakayama; Shoji Sugii; Yoshinori Ozawa; Shigeto Tohma
Journal:  J Rheumatol       Date:  2006-08-15       Impact factor: 4.666

6.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

7.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

8.  Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Authors:  D M Lee; P H Schur
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

9.  Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Authors:  Pernille Bøyesen; Mari Hoff; Sigrid Odegård; Glenn Haugeberg; Silje W Syversen; Per I Gaarder; Cecilie Okkenhaug; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

10.  Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

Authors:  Victoria Bejarano; Mark Quinn; Philip G Conaghan; Richard Reece; Anne-Maree Keenan; David Walker; Andrew Gough; Michael Green; Dennis McGonagle; Ade Adebajo; Stephen Jarrett; Sheelagh Doherty; Lesley Hordon; Richard Melsom; Kristina Unnebrink; Hartmut Kupper; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10-15
View more
  8 in total

1.  Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.

Authors:  Georgia Barouta; Christina G Katsiari; Ioannis Alexiou; Christos Liaskos; Areti Varna; Dimitrios P Bogdanos; Anastasios E Germenis; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2016-12-10       Impact factor: 2.980

2.  ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography.

Authors:  Julien Grosse; Edem Allado; Camille Roux; Audrey Pierreisnard; Marion Couderc; Isabelle Clerc-Urmes; Thomas Remen; Éliane Albuisson; Marcelo De Carvalho-Bittencourt; Isabelle Chary-Valckenaere; Damien Loeuille
Journal:  Rheumatol Int       Date:  2019-12-13       Impact factor: 2.631

3.  Characterizing hand and wrist ultrasound pattern in primary Sjögren's syndrome: a case-control study.

Authors:  L K N Guedes; E P Leon; T S Bocate; K R Bonfigliolli; S V Lourenço; E Bonfa; S G Pasoto
Journal:  Clin Rheumatol       Date:  2020-02-19       Impact factor: 2.980

4.  Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing.

Authors:  Miriam Lizette Díaz-Toscano; Eva Maria Olivas-Flores; Soraya Amali Zavaleta-Muñiz; Jorge Ivan Gamez-Nava; Ernesto German Cardona-Muñoz; Manuel Ponce-Guarneros; Uriel Castro-Contreras; Arnulfo Nava; Mario Salazar-Paramo; Alfredo Celis; Nicte Selene Fajardo-Robledo; Esther Guadalupe Corona-Sanchez; Laura Gonzalez-Lopez
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

5.  PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study.

Authors:  Taku Suzuki; Katsunori Ikari; Koichiro Yano; Eisuke Inoue; Yoshiaki Toyama; Atsuo Taniguchi; Hisashi Yamanaka; Shigeki Momohara
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

6.  Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.

Authors:  Tetsuo Kobayashi; Satoshi Ito; Daisuke Kobayashi; Atsushi Shimada; Ichiei Narita; Akira Murasawa; Kiyoshi Nakazono; Hiromasa Yoshie
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

7.  Circulating levels of carbamylated protein and neutrophil extracellular traps are associated with periodontitis severity in patients with rheumatoid arthritis: A pilot case-control study.

Authors:  Chihiro Kaneko; Tetsuo Kobayashi; Satoshi Ito; Noriko Sugita; Akira Murasawa; Kiyoshi Nakazono; Hiromasa Yoshie
Journal:  PLoS One       Date:  2018-02-02       Impact factor: 3.240

8.  A Retrospective Study: The Significance of Combined Testing of Serum Markers for Diagnosis of Rheumatoid Arthritis.

Authors:  Fangxiang Mu; Hong Wu; Yong Wang
Journal:  Med Sci Monit Basic Res       Date:  2017-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.